DMPK and myotonic dystrophy type 1: This experimental drug for DM1 is designed to induce knockdown of DMPK-CUGexp transcripts through the RNase H pathway, thereby rescuing muscle cells from the pathogenic effects of splicing mis-regulation6,8.